Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Liabilities and Shareholders Equity (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $1.7 billion as the latest value for Q1 2026.

  • For Q1 2026, Liabilities and Shareholders Equity rose 81.75% year-over-year to $1.7 billion; the TTM value through Mar 2026 reached $5.6 billion, up 50.24%, while the annual FY2025 figure was $1.7 billion, 78.2% up from the prior year.
  • Liabilities and Shareholders Equity hit $1.7 billion in Q1 2026 for Kymera Therapeutics, down from $1.7 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.7 billion in Q4 2025 and bottomed at $523.4 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $877.8 million, with a median of $826.0 million recorded in 2024.
  • Year-over-year, Liabilities and Shareholders Equity decreased 13.48% in 2023 and then skyrocketed 87.34% in 2024.
  • Kymera Therapeutics' Liabilities and Shareholders Equity stood at $603.1 million in 2022, then decreased by 4.54% to $575.8 million in 2023, then soared by 69.87% to $978.0 million in 2024, then soared by 78.2% to $1.7 billion in 2025, then dropped by 4.23% to $1.7 billion in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $1.7 billion, $1.7 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.